Compliancy Group Helps Nanodropper Inc. Achieve HIPAA Compliance

Compliancy Group has announced that the medical device company Nanodropper Inc. has implemented an effective HIPAA compliance program and has demonstrated compliance with the Privacy, Security, Omnibus, and Breach Notification Rules of the Health Insurance Portability and Accountability Act (HIPAA).

Nanodropper was inspired by a ProPublica article that revealed drug companies were making eyedrop bottles that deliver eye drops containing more liquid that the human eye can hold, which results in considerable waste and unnecessary costs for patients. Nanodropper developed a first-of-its-kind patient-centered adaptor that fits on eyedrop bottles and reduces the volume of currently oversized eyedrops by more than 60 percent.

The Nanodropper device, after which the company is named, is a FDA-listed, Class I medical device, that reduces cost and waste and helps to minimize potential side effects of vision-saving treatments. In addition to this flagship product, Nanodropper offers value-based solutions to close health equity gaps while promoting patient education and advocacy.

As a manufacturer of medical devices, Nanodropper comes into contact with protected health information. Under HIPAA, any entity that is provided with identifiable healthcare data is required to comply with the HIPAA Rules and must implement safeguards to ensure the confidentiality, integrity, and availability of identifiable protected health information.

To ensure the company was fully compliant with the HIPAA Rules, Nanodropper sought assistance from Compliancy Group. Nanodropper used Compliancy Group’s proprietary HIPAA methodology, The Guard compliance tracking software, and completed its 6-stage risk analysis and remediation process, after which Nanodropper was awarded the HIPAA Seal of Compliance. The HIPAA Seal of Compliance demonstrates Nanodropper’s commitment to HIPAA compliance and helps the firm differentiate its services.

“As our brand continues to be more recognized by the patients we serve, we want them to know that we value our patients’ privacy and think this should be the standard for anyone involved in healthcare,” said Nanodropper CEO Allisa Song. “Patients with diseases like glaucoma can save thousands of dollars per year just by using the Nanodropper with their prescribed eyedrop medication. A purchase with us does not require providing much, if any, medical information, but for anyone providing PHI, rest assured our top priority is keeping that information as safe and secure as possible.”

Author: Steve Alder has many years of experience as a journalist, and comes from a background in market research. He is a specialist on legal and regulatory affairs, and has several years of experience writing about HIPAA. Steve holds a B.Sc. from the University of Liverpool.